What is the present valuation and projected CAGR of the chlamydia market?
The chlamydia market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to the rise in sexual health education programs, the rise in demand for rapid diagnostic tests, the increase in the need for cost-effective and scalable STI diagnostics, the increase in the growth of telemedicine, and the increase in focus on precision medicine.
The chlamydia market size is expected to see strong growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to the increasing prevalence of chlamydia, increasing public awareness, a growing number of point-of-care testing solutions, increasing prevalence of sexually transmitted diseases, and increasing investments in research and development. Major trends in the forecast period include a shift towards point-of-care testing, advancements in molecular diagnostics, a shift towards preventative healthcare, the integration of artificial intelligence (AI) in diagnostics, and the development of high-throughput screening platforms.
Get Your Free Sample of The Global Chlamydia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp
What key drivers have fueled the chlamydia market’s development over the years?
The increasing prevalence of sexually transmitted diseases is expected to propel the growth of the chlamydia market going forward. Sexually transmitted diseases (STDs) refer to infections that spread through sexual contact, including chlamydia, gonorrhea, and HIV. The rise in STDs is attributed to factors such as decreased condom use, lack of awareness, limited access to healthcare, and the prevalence of dating apps that facilitate multiple sexual partners. Chlamydia treatment helps reduce the spread of STDs by eliminating the infection, preventing complications, and lowering the risk of transmission to sexual partners. For instance, in June 2024, according to the National Association of County and City Health Officials, a US-based non-profit organization, in 2022, the U.S. saw over 2.5 million cases of syphilis, gonorrhea, and chlamydia, with syphilis cases rising by 80% and congenital syphilis cases increasing by 937%. A total of 3,755 congenital syphilis cases were reported, marking a 31% increase from 2021 to 2022. Therefore, the increasing prevalence of sexually transmitted diseases is driving the growth of the chlamydia market.
Telemedicine Services Expansion Driving Growth In The Market
The expansion of telemedicine services is expected to propel the growth of the chlamydia market going forward. Telemedicine services refer to the use of digital communication technologies, such as video calls, mobile apps, and remote monitoring tools, to provide healthcare services remotely. The expansion of telemedicine services is attributed to advancements in digital health technologies, increased access to high-speed internet, and the growing demand for remote healthcare options. Chlamydia benefits from telemedicine by enabling patients to access remote consultations, secure prescriptions, and discreet follow-up care, all of which enhance convenience and improve timely treatment adherence. For instance, in April 2023, FAIR Health Inc., a US-based non-profit organization, reported a 7.3% national increase in telehealth usage, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Moreover, in February 2023, according to Rock Health, a US-based venture capital firm, in our 2022 survey, 80% of respondents reported having used telemedicine at some point in their lives, reflecting an 8-percentage-point increase from 72% in 2021. Therefore, the expansion of telemedicine services is driving the growth of the chlamydia market.
What is the segmentation for the chlamydia market?
The chlamydia market covered in this report is segmented –
1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture
2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)
3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection
4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot
5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report
Who are the most influential companies in the chlamydia market?
Major companies operating in the chlamydia market are Pfizer Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca, Abbott Laboratories, GlaxoSmithKline Plc, Gilead Sciences Inc., Danaher Corporation, Becton, Dickinson and Company, Hologic Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co. Ltd., MedMira Inc., GenMark Diagnostics Inc., Aytu BioScience Inc., ACON Laboratories, Inc., Biocartis Group NV, Inova Diagnostics Inc., Trinity Biotech Plc, Laxai Pharma Ltd.
What are the top industry trends projected to impact the chlamydia market?
Major companies operating in the chlamydia market are focusing on developing fully automated instruments to enhance diagnostic accuracy, reduce human error, and improve testing efficiency. A fully automated instrument refers to a device or system that performs tasks without human intervention, typically using sensors, control systems, and artificial intelligence to carry out its functions autonomously. For instance, in May 2022, BD (Becton, Dickinson and Company), a US-based medical device company, launched the BD COR MX/PX System. The BD CTGCTV2 molecular assay is the first test available on the new system. This single test detects the three most common non-viral sexually transmitted infections (STIs)—chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), and trichomonas vaginalis (TV). These STIs can lead to various negative health outcomes for patients, including pregnancy complications and an elevated risk of HIV.
What are the major regional insights for the chlamydia market, and which region holds the top position?
North America was the largest region in the chlamydia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chlamydia Market Report 2025 Offer?
The chlamydia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chlamydia is a common sexually transmitted infection (STI) caused by Chlamydia trachomatis, often asymptomatic but potentially leading to complications like infertility and pelvic inflammatory disease. It is easily treatable with antibiotics, and prevention includes safe sex practices and regular STI screenings.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21138
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
